| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911804 | Lung Cancer | 2005 | 6 Pages |
Abstract
Single-agent irinotecan in this dose and schedule has considerable toxicity in patients with malignant mesothelioma and has no anti-tumor activity. The relatively long median survival seen in this study principally reflects the prognostic features of the accrued patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Hedy L. Kindler, James E. Herndon, Chunfeng Zhang, Mark R. Green, for the Cancer and Leukemia Group B for the Cancer and Leukemia Group B,